Mallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Retrieved on:
Monday, May 3, 2021
Monitor patients for effects of HPA axis suppression after stopping treatment\nCushing\'s syndrome may occur during therapy but generally resolves after therapy is stopped.
Key Points:
- Monitor patients for effects of HPA axis suppression after stopping treatment\nCushing\'s syndrome may occur during therapy but generally resolves after therapy is stopped.
- Monitor patients for signs and symptoms\nActhar can cause elevation of blood pressure, salt and water retention, and hypokalemia.
- Monitor blood pressure and sodium and potassium levels\nActhar often acts by masking symptoms of other diseases/disorders.
- Monitor patients carefully during and for a period following discontinuation of therapy\nActhar can cause gastrointestinal (GI) bleeding and gastric ulcer.